Teva Pharmaceuticals and Iontas have partnered to optimize human antibodies to be used for biotherapeutics. Iontas will provide Teva with optimized antibodies for a specific target, with the latter gaining the option to be part of future optimization programs.
Teva, Iontas enter deal for biotherapeutics development
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.